Skip to main content

Staging

Patients with biopsy-confirmed CTCL are staged according to the extent of their skin disease and treatment is determined by their stage. The staging system used is as follows:

T0

No skin involvement

T1

Patches or plaques, covering<10% of the body surface

T2

Same as above but covering >10% of the body surface

T3

Tumors with or without patches or plaques

T4

Generalized erythema

NP0

No abnormal peripheral lymph nodes

NP1-   

Abnormal peripheral lymph nodes, biopsy negative

 

(i.e., dermatopathic lymphadenopathy)

NP1+

Abnormal peripheral lymph nodes, biopsy positive

NV0

No abnormal visceral lymph nodes

NV1

Abnormal visceral lymph nodes (no information regarding biopsy)

NV1-

Abnormal visceral lymph nodes, biopsy negative

NV1+

Abnormal visceral lymph nodes, biopsy positive

M0

No visceral organ involvement

M1

Visceral organ involvement (on basis of histology)

B0

<5% circulating Sézary cells and <250 Sézary cells per cc

B1

>5% circulating Sézary cells, or>250 Sézary cells per cc

Prior to staging, each patient has a careful clinical examination. If any superficial lymph nodes are enlarged, and the disease is otherwise clinically confined to the skin, the largest node is biopsied. A CT scan of the abdomen and pelvis is done to assess the intra-abdominal and pelvic lymph nodes. If an abnormal node is demonstrated, (usually in the pelvis) and the disease is clinically confined to the skin, biopsy is considered. A quantitative Sézary cell count is performed to assess the presence and number of circulating lymphoma cells as well as a CBC and LDH.​

SOURCE: Staging ( )
Page printed: . Unofficial document if printed. Please refer to SOURCE for latest information.

Copyright © BC Cancer. All Rights Reserved.

    Copyright © 2021 Provincial Health Services Authority